COMMUNIQUÉS West-GlobeNewswire
-
Galecto Reports Third Quarter 2024 Financial Results
01/11/2024 - 13:30 -
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
01/11/2024 - 13:30 -
RTI Surgical Completes Acquisition of Collagen Solutions
01/11/2024 - 13:38 -
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
01/11/2024 - 14:00 -
Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical
01/11/2024 - 14:15 -
Milestone Scientific Expands Commercial Rollout of the CompuFlo® Epidural System with Esteemed Pain Management Physician Dr. Elbaz at Hudson Specialty Care
01/11/2024 - 14:15 -
Safety Shot Expands Distribution to Chicagoland Grocery Stores
01/11/2024 - 14:45 -
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
01/11/2024 - 15:34 -
Legend Senior Living® Will Operate Newly Renamed Ridgecrest at Cranberry Woods Senior Living Residence
01/11/2024 - 16:21 -
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
01/11/2024 - 17:30 -
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
01/11/2024 - 18:00 -
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
01/11/2024 - 19:00 -
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
01/11/2024 - 20:05 -
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
01/11/2024 - 21:00 -
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
01/11/2024 - 21:01 -
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/11/2024 - 21:05 -
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/11/2024 - 21:05 -
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01/11/2024 - 21:05 -
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01/11/2024 - 21:30
Pages